NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Manifold Bio

Manifold Bio

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.manifold.bio/

Last Round

Series A

Extension

Dec 3, 2024

Total Funding Raised

$78.18M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Manifold Bio is a biotechnology company that develops a high-throughput in vivo discovery engine integrating multiplexed screening with AI-powered protein design to create tissue-targeted biologics.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

biologics designdrug discoveryin vivo screeningbrain shuttlesprotein engineeringblood-brain barrierai drug discoveryin silico drug designtargeted therapeuticsneurological diseasebiotech platformin vivo-firstdrug deliveryai-guided designcomputational biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Manifold Bio Comparables

Compare Manifold Bio with similar companies based on industry and business-model similarity.

Manifold Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Dyno Therapeutics
82%
Gate2Brain
78%
Cenos Therapeutics
76%

Manifold Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionDec 3, 2024
Series AJul 14, 2022
SeedSep 8, 2020

Key People

Founding team and executive leadership

Pierce Ogden

Co-Founder, CTO And Board Director

Founding Team

Gleb Kuznetsov

Co-Founder And CEO

Founding Team

Manifold Bio Investors

Notable investors and investment history

Manifold Bio investors
InvestorRounds
S32Series A
Horizons VenturesSeries A
Harvard Innovation Launch LabSeed
Harvard Innovation LabsSeed
Triatomic CapitalSeries A
Playground GlobalSeries A, Seed
FAST--by GETTYLABSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    Generative antibody design model mBER is now available.

  • Nov 3, 2025

    Focuses on AI-guided drug discovery through a license agreement.

Manifold Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Manifold Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Manifold Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range69
Year Founded2019
Last FundingDec 3, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.